The US Food and Drug Administration (FDA) has approved the first treatment for thymidine kinase 2 deficiency (TK2d), paving the way for landmark treatment options for the mitochondrial disease. 

Doxecitine and doxribtimine, approved by the FDA, are oral solutions developed by biopharmaceutical company UCB. The powder, also known as Kygevvi, has been approved for use in adults and paediatric patients with an age of symptom onset on or before 12 years. 

TK2d is an ultra-rare, life-threatening, genetic mitochondrial disease characterised by progressive (worsening over time) and severe muscle weakness (myopathy). It is often fatal, with those experiencing initial symptoms on or before the age of 12 years facing a high risk of premature death (often occurring within three years after symptom onset). It is estimated that the worldwide prevalence of TK2d is 1.64 cases per 1,000,000 people. 

“The approval of doxecitine and doxribtimine represents a pivotal moment for the TK2d community who previously had no FDA-approved treatment options for this rare genetic mitochondrial disease beyond supportive [palliative] care,” said Donatello Crocetta, Chief Medical Officer at UCB.  

“We extend heartfelt thanks to the patients, families and friends, advocates, healthcare providers and dedicated clinical trial teams who have partnered with us on this important journey.” 

TK2d ‘in dire need of treatment options’

The Kygevvi approval follows safety and efficacy data from a Phase II clinical study, two retrospective chart review studies, and an expanded access use programme. These studies included a total of 82 unique patients treated with Kygevvi or pyrimidine nucleosides with an age of TK2d symptom onset ≤12 years. 

The results showed that survival time from treatment start was improved and treatment reduced the overall risk of death from treatment start by approximately 86%. Of the 78 treated patients included in the survival analysis, the median age of TK2d symptom onset was 1.5 years, with median duration of treatment being four years. 

Kristen Clifford, United Mitochondrial Disease Foundation President and CEO, added that it was “hard to overstate the importance of this FDA approval.”

“This is an ultra-rare disease community in dire need of treatment options,” she said. “For too long, caregivers and their families have had to endure the burden of this disease.  

“Having the first-ever FDA-approved therapy for TK2d in this patient population not only meets a critical medical need. It represents something greater – hope for the future.” 

 Kygevvi is not currently approved for use in any indication by any regulatory authority outside of the US. 

 

Bruno Quinney, Content Team, DDW